SCHEMBL5338426

SCHEMBL5338426

CC(S)S(C)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030219 0.75
SCHEMBL92892 0.73
SCHEMBL126328 0.72
SCHEMBL2446519 0.70
SCHEMBL30896661 0.70 KDM4E (0.42)
Ammonia Solution, Strong SCHEMBL31591123 0.70
SCHEMBL1149141 0.70 KDM4E (0.42)
Lithium Ion SCHEMBL3271653 0.69
SCHEMBL313226 0.69
Potassium Ion SCHEMBL6316224 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113271975-A Method and kit for preparing pathogen inactivated whole blood 塞鲁斯公司 2021-08-17 CN disclosed
US-20160347814-A1 VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES COMPUGEN LTD (IL) 2016-12-01 US disclosed
US-20160272707-A1 VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES COMPUGEN LTD. (IL) 2016-09-22 US disclosed
US-7293985-B2 Methods for quenching pathogen inactivators in biological materials CERUS CORPORATION (US) 2007-11-13 US disclosed
EP-1045704-B1 METHODS FOR QUENCHING PATHOGEN INACTIVATORS IN BIOLOGICAL MATERIALS CERUS CORP (US) 2004-09-22 EP disclosed
US-20040180321-A1 Methods for quenching pathogen inactivators in biological materials CERUS CORPORATION (US) 2004-09-16 US disclosed
WO-2004050897-A2 METHODS FOR PREPARING ANTIGEN MASKED RED BLOOD CELLS HAVING REDUCED HEMOLYSIS BY SERA CERUS CORPORATION (US) 2004-06-17 WO disclosed
WO-2004050848-A2 METHODS FOR ANTIGEN MASKING OF RED BLOOD CELLS RESULTING IN REDUCED HEMOLYSIS CERUS CORPORATION (US) 2004-06-17 WO disclosed
WO-2004049914-A2 METHODS FOR REACTING AN ANTIGEN MASKING COMPOUND WITH RED BLOOD CELLS WITH HIGH EFFICIENCY CERUS CORPORATION (US) 2004-06-17 WO disclosed
US-6709810-B2 SIDE EFFECT REDUCTION USING QUENCHER; STORAGE STABILITY CERUS CORPORATION 2004-03-23 US disclosed
US-6093725-A A BINDER FOR DEACTIVATING PATHOGENS IN A BLOOD SAMPLE TO BIND NUCLEIC ACID BY COVALENT LINKAGE CERUS CORPORATION (US) 2000-07-25 US disclosed
EP-1005531-A2 METHOD OF TREATING LEUKOCYTES, LEUKOCYTE COMPOSITIONS AND METHODS OF USE THEREOF Cerus Corporation (US) 2000-06-07 EP disclosed
WO-1999063981-A2 USE OF ALKYLATING COMPOUNDS FOR INHIBITING PROLIFERATION OF ARTERIAL SMOOTH MUSCLE CELLS CERUS CORPORATION (US) 1999-12-16 WO disclosed
WO-1999034839-A1 METHODS FOR QUENCHING PATHOGEN INACTIVATORS IN BIOLOGICAL MATERIALS CERUS CORPORATION (US) 1999-07-15 WO disclosed
US-5880076-A PERSONAL PRODUCT OR DETERGENT COMPOSITION COMPRISING CYCLIC GLYCACARBAMATE AND/OR GLYCAUREA, SURFACTANT LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1999-03-09 US disclosed
WO-1999003976-A2 METHOD OF TREATING LEUKOCYTES, LEUKOCYTE COMPOSITIONS AND METHODS OF USE THEREOF CERUS CORPORATION (US) 1999-01-28 WO disclosed
WO-1998030545-A9 FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION 1998-12-30 WO disclosed
WO-1998030545-A1 FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION CERUS CORPORATION (US) 1998-07-16 WO disclosed
US-5641480-A ENHANCED STABILITY AND/OR VISCOSITY, CLARITY LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1997-06-24 US disclosed
US-5041286-A Appying oxidizing solution without rinsing reducing solution YASMIN PRODUCTS PTY. LIMITED (AU) 1991-08-20 US disclosed